← Leaderboards
Laura S Angelo
Marker Therapeutics, Inc.
$997,257
Attributed
$1,994,514
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $664.8K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,994,514 · 1
By mechanism
R44$1,994,514 · 1
Top collaborators
- Juan Fernando Vera3 shared
Most similar at Marker Therapeutics, Inc.
Same institution · by research overlap
- Juan Fernando Vera$7,624,284
- Brandon Smaglo$674,275
Others in their field
Other Rising Stars on “Acute Myelocytic Leukemia”
- Michael E. Roth · Public Health Institute$8,303,012
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Kellie Bickel · Twinstrand Biosciences, Inc.$2,555,383
- Jeevisha Bajaj · University Of Rochester$2,438,184
- Bruno Di Stefano · Baylor College Of Medicine$2,398,360
- Angela Goffredo Fleischman · University Of California-Irvine$2,306,090
Research focus
Acute Myelocytic LeukemiaAdjuvantAdverse EventAcute Myeloid Leukemia CellAnimal ModelAntigensAntigen-Specific T CellsAntigen TargetingAllogenicAuthorization DocumentationAzacitidineBenefits And RisksBiological MarkersBlood Component RemovalCancer CellCar T Cell TherapyCd4 Positive T LymphocytesCd8b1 GeneCell KillingCellsCell TherapyCharacteristicsChemotherapyClinical Research
Grant awards (3)
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2025 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2024 · CA
Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant$664,838
R44 · FY2023 · CA